SCHEMBL30765447

SCHEMBL30765447

CCCCOC(=O)Cn1c(-c2ccccc2)ncc(Br)c1=O

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.65
GAA P10253 2/20 0.65
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
LMNA P02545 2/20 0.48
TSHR P16473 2/20 0.48
MAPK1 P28482 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
POLB P06746 2/20 0.47
MAPT P10636 2/20 0.47
ALOX15 P16050 1/20 0.45
CYP3A4 P08684 1/20 0.42
BACE1 P56817 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765592 0.85 L3MBTL1 (0.50) L3MBTL1GAAMEN1KMT2ACYP1A2
SCHEMBL30765438 0.83 KDM4E (0.50) L3MBTL1GAAMEN1KMT2ACYP1A2
SCHEMBL30765660 0.81 KDM4E (0.51) L3MBTL1GAAMEN1KMT2ACYP1A2
SCHEMBL30765839 0.80 MEN1 (0.49) L3MBTL1GAAMEN1KMT2ALMNA
SCHEMBL30765667 0.80 GAA (0.56) L3MBTL1GAAMEN1KMT2ACYP1A2
SCHEMBL30765661 0.79 MEN1 (0.48) L3MBTL1GAAMEN1KMT2ALMNA
SCHEMBL30766020 0.77 MEN1 (0.46) L3MBTL1GAAMEN1KMT2ALMNA
SCHEMBL30765740 0.76 MEN1 (0.45) L3MBTL1GAAMEN1KMT2ALMNA
SCHEMBL31558509 0.76 ALDH1A1 (0.49) L3MBTL1GAAMEN1KMT2ACYP1A2
SCHEMBL30765514 0.75 ALDH1A1 (0.48) L3MBTL1GAAMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed